DOCSLIB.ORG

Abstract Book – Oral Sessions

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Book – Oral Sessions Sunday, June 21, 2015 12:00 p.m. - 1:15 p.m. Latin American Psychopharmacology Update: INNOVATIVE TREATMENTS IN PSYCHIATRY INNOVATIVE TREATMENTS IN PSYCHIATRY Flavio Kapczinski, The University of Texas Health Science Center at Houston Overall Abstract In this panel, we will propose innovative treatments in psychiatry and recent literature findings will be summarized. The effective pharmacological treatment of psychiatric diseases and development of new therapeutic entities has been a long-standing challenge. Despite the complexity and heterogeneity of psychiatric disorders, basic and clinical research studies and technological advancements in genomics, biomarkers, and imaging have begun to elucidate the pathophysiology of etiological complexity of psychiatric diseases and to identify efficacious new agents (Tcheremissine et al. 2014). Many psychiatric illnesses are associated with neuronal atrophy, characterized by loss of synaptic connections, increase of inflammatory markers like TNF-α and DAMPS (damage-associate molecular patterns,- cell free (ccf) DNA, heat shock proteins HSP70, HSP90, and HSP60, and cytochrome C), decrease of neurotrophic factors, increase of oxidative stress, mitochondrial dysfunction and apoptosis (Fries et al., 2012; Pfaffenseller et al., 2014). Also, neurocognitive impairment and poor psychosocial functioning has been related to a psychiatric disease. Therefore, trying to discover new therapeutic targets that act in these pathways can help to develop new treatment or improve the treatment of these serious diseases. Furthermore, prompt treatment may be potentially neuroprotective and attenuate the neurostructural and neurocognitive changes that emerge with chronicity in patients with severe psychiatric disorders. Learning Objectives Describe studies to develop new therapeutic targets to treatment of psychiatric disease. Learning about new strategies to treat psychiatric disease SODIUM NITROPRUSSIDE AS A FAST-ACTING ANTIPSYCHOTIC AGENT Jamie Hallak, University of São Paulo Individual Abstract Despite decades of study, the etiology and physiopathology of schizophrenia remain unknown. Recent evidence suggests that nitric oxide (NO) may be implicated in schizophrenia. NO is a gas that mediates the release of neurotransmitters, learning, memory, and neurodevelopment. Studies investigating the role of NO in patients with schizophrenia found evidence that points to a disruption in NO- mediated neurotransmission. Therefore, we investigated the effects of sodium nitroprusside, an NO donor, as an add-on treatment for patients with schizophrenia. Twenty adult schizophrenia patients treated with stable doses of antipsychotics were randomly assigned to two groups that received an infusion of either sodium nitroprusside or placebo for four hours. Psychiatric symptoms were assessed at baseline and every hour during the infusion with the Brief Psychiatric Rating Scale (BPRS) and the negative subscale of the Positive and Negative Syndromes Scale (PANNS-n). Additional assessments were made 12 hours after the infusion, daily for seven days, and weekly for four weeks. Cognitive tests (Stroop Color Word Test, N-back, and FAS) were administered at baseline and 12 hours after the end of the infusion. No side effects were reported by the participants. All the clinical and demographic characteristics of the sample including age, education, duration of disease, gender, diagnostic subtype, and type of antipsychotic in use were matched across groups. Symptom ratings were significantly reduced in the group treated with sodium nitroprusside, but not in the placebo group. Cognitive performance was also significantly improved in the nitroprusside group compared to placebo. There were no significant differences between the two groups regarding the physiological parameters analyzed (systolic and diastolic blood pressure, cardiac rhythm, and oxygen saturation). The strategy of treating schizophrenia patients for four hours with 0,5 mcg/kg/min sodium nitroprusside improved psychopathology and cognitive function. Our findings support the hypothesis that the NMDA-NO-GMPc pathway is affected in schizophrenia and that nitric oxide donors such as sodium nitroprusside could thus be a promising approach in the management of the disorder. Although exciting, these results are preliminary and must be replicated by future studies. Learning Objectives Role of NO in schizophrenia NO donors as a therapeutical approach in schizophrenia Literature References Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo- controlled trial. JAMA Psychiatry. 2013 Jul;70(7):668-76. Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB, Dursun SM, Hallak JE. The effects of sodium nitroprusside treatment on cognitive deficits in schizophrenia: a pilot study. J Clin Psychopharmacol. 2015 Feb;35(1):83-5. DEEP BRAIN STIMULATION: NEW OPPORTUNITIES IN NEUROPSYCHIATRY Roger Walz, AFSC Individual Abstract Deep brain stimulation (DBS) consists of a neural-network modulation of dysfunctional brain circuits by electric stimulation through steretatically implanted electrodes. The technique has been successfully applied to treat movement disorders. Several reports raise the possible use of DBS to treat pharmacologically refractory neuropsychiatric diseases including: depression, obsessive- compulsive disorder, Gilles de la Tourrete, addictive behavior, obesity, anorexia nervosa, Alzheimer´s, epilepsies and aggressive behavior. The mechanisms of DBS action remain unknown, and understanding the effects of electrical stimulation on brain functions is a fascinating opportunity for basic and clinical research. DBS is an expanding area that offers an endless array for multidisciplinary research involving physicians, engineers and basic neuroscientists. We will discuss some of the promising and challenges aspects related to the clinical applications of DBS in neuropsychiatry. Learning Objectives To present some possible applications of DBS in neuropsychiatry To discuss some challenges related to DBS clinical use in neuropsychiatric diseases Literature References Williams NR and Okun MS. Deep brain stimulation (DBS) at the interface of neurology and psychiatry. J Clin Invest 2013;123: 4546–4556. Krack P, Hariz MI, Baunez C, Guridi J, and Obeso JA. Deep brain stimulation: from neurology to psychiatry? TINS 2010; 33: 474-484. 1:15 p.m. - 2:30 p.m. Latin American Psychopharmacology Update: NEW PHARMACOLOGICAL TARGETS: FROM PRE- CLINICAL MODELS TO PATIENT CARE NEW PHARMACOLOGICAL TARGETS: FROM PRE-CLINICAL MODELS TO PATIENT CARE Marco Romano-Silva, Universidade Federal de Minas Gerais Overall Abstract The number of non-responding patients to current treatments is still unacceptably high, reaching 30% or more in some disorders. Thus, the search for new targets is essential and urgent. Identification of new targets for pharmacological therapy of psychiatric disorders will be presented in this session, with focus on major depression, late life depression and schizophrenia. Learning Objectives To discuss new strategies for the treatment of major depressive disorder and late life depression. To discuss the efficacy of memantine as an adjunctive treatment in schizophrenia. NEUROCHEMICAL MECHANISMS UNDERLYING KETAMINE ANTIDEPRESSANT EFFECT João de Quevedo, The University of Texas Health Science Center at Houston Individual Abstract Major depressive disorder (MDD) affects about 121 million of global population and poses a significant burden to the healthcare sector. Nevertheless, around 50-60% of patients with MDD respond adequately to existing treatments. In addition, the neurobiology of MDD as well as drug action mechanism is not yet fully elucidated. Recently, studies have demonstrated the key role of the glutamatergic system in both pathophysiology and treatment of MDD. Ketamine, an N-methyl-D-asparte (NMDA) receptor antagonist has been proposed as potential revolutionary rapid antidepressant agents for treatment-resistant mood disorders. Preclinical studies have been shown that ketamine stimulate the mammalian target of rapamycin (mTOR), which is involved in neuroplasticity, cell survival and proliferation, including brain-derived neurotrophic factor (BDNF) and MAPK signaling. In addition, ketamine decreases oxidative stress and inflammation in rodents subjected to animal models of depression. Thus, current and future research studies are using ketamine as a promising tool to evaluate the glutamatergic neurotransmitter system to learn more about the pathophysiology of depression and develop more specific rapid-acting antidepressant treatments. Thus, this panel will summarize recent findings from literature. Learning Objectives New strategies to major depressive disorder treatment. Preclinical and clinical studies showing evidences that glutamatergic system is involved with depression. Literature References Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA Jr: Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 2015, in press. Réus GZ, Nacif MP, Abelaira HM, Tomaz DB, dos Santos MA, Carlessi AS, da Luz JR, Gonçalves RC, Vuolo F, Dal-Pizzol F, Carvalho AF, Quevedo J: Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation.
Load more

Recommended publications
  • Brain Metabolic Profile After Intranasal Vs. Intraperitoneal Clomipramine
    International Journal of Molecular Sciences Article Brain Metabolic Profile after Intranasal vs. Intraperitoneal Clomipramine Treatment in Rats with Ultrasound Model of Depression Olga Abramova 1,2, Yana Zorkina 1,2,* , Timur Syunyakov 2,3 , Eugene Zubkov 1, Valeria Ushakova 1,2, Artemiy Silantyev 1, Kristina Soloveva 2, Olga Gurina 1, Alexander Majouga 4, Anna Morozova 1,2 and Vladimir Chekhonin 1,5 1 V. Serbsky National Medical Research Centre of Psychiatry and Narcology, 119034 Moscow, Russia; [email protected] (O.A.); [email protected] (E.Z.); [email protected] (V.U.); [email protected] (A.S.); [email protected] (O.G.); [email protected] (A.M.); [email protected] (V.C.) 2 Mental-Health Clinic No. 1 Named after N.A. Alekseev, 117152 Moscow, Russia; [email protected] (T.S.); [email protected] (K.S.) 3 Federal State Budgetary Institution Research Zakusov Institute of Pharmacology, 125315 Moscow, Russia 4 Drug Delivery Systems Laboratory, D. Mendeleev University of Chemical Technology of Russia, Miusskaya pl. 9, 125047 Moscow, Russia; [email protected] 5 Department of Medical Nanobiotechnology, Pirogov Russian National Research Medical University, 117997 Moscow, Russia * Correspondence: [email protected]; Tel.: +7-916-588-4851 Citation: Abramova, O.; Zorkina, Y.; Abstract: Background: Molecular mechanisms of depression remain unclear. The brain metabolome Syunyakov, T.; Zubkov, E.; Ushakova, after antidepressant therapy is poorly understood and had not been performed for different routes V.; Silantyev, A.; Soloveva, K.; Gurina, of drug administration before the present study. Rats were exposed to chronic ultrasound stress O.; Majouga, A.; Morozova, A.; et al. and treated with intranasal and intraperitoneal clomipramine.
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: January 2015 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 January 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • Understanding Exposure-Receptor Occupancy Relationships For
    1521-0103/377/1/157–168$35.00 https://doi.org/10.1124/jpet.120.000371 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 377:157–168, April 2021 Copyright ª 2021 by The Author(s) This is an open access article distributed under the CC BY Attribution 4.0 International license. Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies Kirstie A. Bennett, Eugenia Sergeev, Cliona P. MacSweeney, Geor Bakker, and Anne E. Cooper Sosei Heptares, Cambridge, CB21 6DG, United Kingdom Received October 9, 2020; accepted January 26, 2021 Downloaded from ABSTRACT The metabotropic glutamate receptor 5 (mGlu5) is a recog- a unified exposure-response relationship was observed when nized central nervous system therapeutic target for which both unbound brain concentration and mGlu5 affinity were several negative allosteric modulator (NAM) drug candidates considered. This relationship showed ,10-fold overall differ- have or are continuing to be investigated for various disease ence, was fitted with a Hill slope that was not significantly indications in clinical development. Direct measurement of different from 1, and appeared consistent with a simple Emax jpet.aspetjournals.org target receptor occupancy (RO) is extremely useful to help model. This is the first time this type of comparison has been design and interpret efficacy and safety in nonclinical and conducted, demonstrating a unified brain exposure-RO re- clinical studies. In the mGlu5 field, this has been success- lationship across several species and mGlu5 NAMs with fully achieved by monitoring displacement of radiolabeled diverse properties.
    [Show full text]
  • LJMU Research Online
    LJMU Research Online Akkus, F, Terbeck, S, Haggarty, CJ, Treyer, V, Dietrich, JJ, Hornschuh, S and Hasler, G The role of the metabotropic glutamate receptor 5 in nicotine addiction. http://researchonline.ljmu.ac.uk/id/eprint/13456/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Akkus, F, Terbeck, S, Haggarty, CJ, Treyer, V, Dietrich, JJ, Hornschuh, S and Hasler, G (2020) The role of the metabotropic glutamate receptor 5 in nicotine addiction. CNS Spectrums. ISSN 1092-8529 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ Accepted Manuscript: Authors' Copy 1 The role of the metabotropic glutamate receptor 5 in nicotine addiction 2 3 Running head: mGluR5 and nicotine addiction 4 5 Authors: Funda Akkus1,4, Sylvia Terbeck 5, Connor.
    [Show full text]
  • Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Mglu5 Negative Allosteric Modulator in Clinical Development for Depression
    JPET Fast Forward. Published on February 9, 2015 as DOI: 10.1124/jpet.114.222463 This article has not been copyedited and formatted. The final version may differ from this version. JPET #222463 Title page Pharmacology of basimglurant (RO4917523, RG7090), a unique mGlu5 negative allosteric modulator in clinical development for depression Lothar Lindemann*, Richard H. Porter, Sebastian H. Scharf, Basil Kuennecke, Andreas Bruns, Markus von Downloaded from Kienlin, Anthony C. Harrison, Axel Paehler, Christoph Funk, Andreas Gloge, Manfred Schneider, Neil J. Parrott, Liudmila Polonchuk, Urs Niederhauser, Stephen R. Morairty, Thomas S. Kilduff, Eric Vieira, Sabine jpet.aspetjournals.org Kolczewski, Juergen Wichmann, Thomas Hartung, Michael Honer, Edilio Borroni, Jean-Luc Moreau, Eric Prinssen, Will Spooren, Joseph G. Wettstein, Georg Jaeschke at ASPET Journals on September 27, 2021 Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience, Ophthalmology, and Rare Diseases (NORD) (L.L., S.H.S., B.K., A.B., M.v.K., M.H., E.B., E.P., W.S., J.G.W.), Discovery Chemistry (E.V., S.K., J.W., G.J.), Operations for Neuroscience, Ophthalmology, and Rare Diseases (R.H.P., J.-L.M.), Pharmaceutical Sciences (A.H., A.P., C.F., A.G., M.S., N.P., L.P., U.N.), Small Molecules Process Research and Synthesis (T.H.), Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel, Switzerland Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, California 94025, USA (S.R.M., T.S.K.) 1 JPET Fast Forward. Published on February 9, 2015 as DOI: 10.1124/jpet.114.222463 This article has not been copyedited and formatted.
    [Show full text]
  • 'Party Drug' Turned Antidepressant Approaches Approval
    NEWS & ANALYSIS Nature Reviews Drug Discovery | Published online 30 Oct 2018; doi:10.1038/nrd.2018.187 ‘Party drug’ turned anti depressant approaches approval Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don’t understand how the fast-acting antidepressant lifts moods. DrAfter123/DigitalVision Vectors Sara Reardon Monteggia, a neuroscientist at Vanderbilt later learned that the antibiotic, at low doses, University. blocks the NMDA receptor, a glutamate When researchers showed in 2006 that the Yet it is far from clear how this work will receptor. Then in the late 1990s,Nature when Reviews | Drug Discovery anaesthetic ketamine — also known as the play out. Whereas early evidence suggested psychiatrist John Krystal of Yale University club drug Special K — was a rapid and potent that ketamine acted through the NMDA was curious about whether the antidepressant, big pharmaceutical receptor, many of the first-generation neurotransmitter glutamate contributed to companies quickly jumped into the game. ketamine mimetics that were designed to act schizophrenia, he decided to test the known Extensive efforts to improve on decades-old on this target failed in clinical trials (TABLE 1). NMDA receptor antagonist ketamine in nine antidepressants had floundered, but ketamine Accumulating evidence now suggests that depressed patients. finally promised a novel mechanism of action ketamine’s antidepressant activity may be At the time, glutamate had mostly been and the potential to help treatment-resistant more complicated. studied for its role in learning and memory. But patients. As a result, some companies are quietly Krystal’s group found that ketamine induced a Because ketamine is an old drug and going back to the drawing board.
    [Show full text]
  • Fragile X Targeted Pharmacotherapy: Lessons Learned and Future Directions Craig A
    Erickson et al. Journal of Neurodevelopmental Disorders (2017) 9:7 DOI 10.1186/s11689-017-9186-9 REVIEW Open Access Fragile X targeted pharmacotherapy: lessons learned and future directions Craig A. Erickson1,2*, Matthew H. Davenport1,3, Tori L. Schaefer1, Logan K. Wink1,2, Ernest V. Pedapati1,2, John A. Sweeney2, Sarah E. Fitzpatrick1, W. Ted Brown10, Dejan Budimirovic11,12, Randi J. Hagerman4,5, David Hessl4,6, Walter E. Kaufmann7,8 and Elizabeth Berry-Kravis9 Abstract Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with ways to improve trial execution.
    [Show full text]
  • Depression and Schizophrenia Viewed from the Perspective of Amino Acidergic Neurotransmission: Antipodes of Psychiatric Disorders
    Pharmacology & Therapeutics 193 (2019) 75–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders Joanna M. Wierońska, Andrzej Pilc ⁎ Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Krakow, Poland article info abstract Available online 25 August 2018 Depression and schizophrenia are burdensome, costly serious and disabling mental disorders. Moreover the existing treatments are not satisfactory. As amino-acidergic (AA) neurotransmitters built a vast majority of Keywords: brain neurons, in this article we plan to focus on drugs influencing AA neurotransmission in both diseases: we Glutamate will discuss several facts concerning glutamatergic and GABA-ergic neurotransmission in these diseases, based GABA mainly on preclinical experiments that used stimulators and/or blockers of both neurotransmitter systems. In Depression general a picture emerges showing, that treatments that increase excitatory effects (with either antagonists or Schizophrenia agonists) tend to evoke antidepressant effects, while treatments that increase inhibitory effects tend to display Agonists/positive allosteric modulators Antagonists/negative allosteric modulators antipsychotic properties. Moreover, it seems that the antidepressant activity of a given compound excludes it as a potential antipsychotic and vice versa. © 2018 Elsevier Inc. All rights
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Tuesday, June 23, 2015
    Tuesday, June 23, 2015 Poster Session I T1. THE ANTIDEPRESSANT ACTIVITY OF BASIMGLURANT, A NOVEL MGLU5-NAM; A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY IN THE ADJUNCTIVE TREATMENT OF MDD Jorge Quiroz1, Dennis Deptula1, Ludger Banken2, Ulrich Beyer2, Paulo Fontoura2, Luca Santarelli2 1Roche Innovation Center NY, 2Roche Innovation Center Basel, Switzerland Abstract Background: Therapies targeting the glutamatergic system are known to be efficacious in the treatment of mood disorders. Antagonism of the post-synaptic mGlu5 receptor is a novel approach to indirectly modulate glutamatergic (NMDA) function and has shown efficacy in a number of preclinical behavioral models of depression. Basimglurant is a potent and selective negative allosteric modulator of the mGlu5 receptor which has been comprehensively profiled in Ph1 and Ph2a trials. The main objectives of this Ph2b trial were to evaluate the safety and efficacy of basimglurant modified release (MR) vs. placebo, as adjunctive therapy to ongoing antidepressant treatment in patients with major depressive disorder (MDD) who showed inadequate response to at least one but no more than three treatment failures within the current episode. Methods: In this 9-week study (6-week double-blind treatment, 3-week post-treatment follow- up), adult patients with DSM-IV-TR diagnosis of MDD were randomized to basimglurant 0.5 mg/d, 1.5 mg/d, or placebo (adjunctive to ongoing SSRI or SNRI). The primary endpoint was the mean change from baseline in the Montgomery-Åsberg Depression Rating Scale Sigma total score (MADRS), as rated by the clinician at week 6. Concomitantly, patient-rated MADRS scores were also collected and analyzed.
    [Show full text]
  • Towards Mechanism- Based Treatments for Fragile X Syndrome
    brain sciences Towards Mechanism- based Treatments for Fragile X Syndrome Edited by Daman Kumari and Inbal Gazy Printed Edition of the Special Issue Published in Brain Sciences www.mdpi.com/journal/brainsci Towards Mechanism-based Treatments for Fragile X Syndrome Towards Mechanism-based Treatments for Fragile X Syndrome Special Issue Editors Daman Kumari Inbal Gazy MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editors Daman Kumari Inbal Gazy National Institute of Diabetes National Institute of Diabetes USA USA Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Brain Sciences (ISSN 2076-3425) from 2018 to 2019 (available at: https://www.mdpi.com/journal/ brainsci/special issues/Fragile X Syndrome) For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03921-505-8 (Pbk) ISBN 978-3-03921-506-5 (PDF) Cover image courtesy of Elisa A. Waxman, Children’s Hospital of Philadelphia, Philadelphia, PA, USA. c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND.
    [Show full text]
  • Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Expert Rev Manuscript Author Clin Pharmacol Manuscript Author . Author manuscript; available in PMC 2017 August 10. Published in final edited form as: Expert Rev Clin Pharmacol. 2017 February ; 10(2): 153–166. doi:10.1080/17512433.2017.1253472. Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression Ioline D. Henter1, Rafael T. de Sousa1, Philip W. Gold1, Andre R. Brunoni2, Carlos A. Zarate Jr1, and Rodrigo Machado-Vieira1 1Experimental Therapeutics and Pathophysiology Branch, NIMH-NIH, USA 2Laboratory of Neuroscience, LIM- 27, Institute and Department of Psychiatry, University of São Paulo, São Paulo, Brazil Abstract Introduction—Real-world effectiveness trials suggest that antidepressant efficacy is limited in many patients with mood disorders, underscoring the urgent need for novel therapeutics to treat these disorders. Areas Covered—Here, we review the clinical evidence supporting the use of novel modulators for the treatment of mood disorders, including specific glutamate modulators such as: 1) high- trapping glutamatergic modulators; 2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists; 3) NMDA receptor glycine-site partial agonists; and 4) metabotropic glutamate receptor (mGluR) modulators. We also discuss other promising, non-glutamatergic targets for potential rapid antidepressant effects in mood disorders, including the cholinergic system, the glucocorticoid system, and the inflammation pathway, as well as several additional targets of interest. Clinical evidence is emphasized, and non-pharmacological somatic treatments are not reviewed. In general, this paper only explores agents available in the United States. Expert Commentary—Of these novel targets, the most promising—and the ones for whom the most evidence exists—appear to be the ionotropic glutamate receptors.
    [Show full text]